Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Pre-CAR next generation sequencing informs patient outcomes in children and young adults with B-acute lymphoblastic leukemia

Rohaum Hamidi, Amy Zhang, Malka Handwerker et al. Nov 03, 2025 pp. 550-550 10.1182/blood-2025-550

Abstract Introduction Lower baseline disease burden associates with improved survival in children and young adults with B-cell acute lymphob...

High serum C3 complement levels were associated with poor prognosis of angioimmunoblastic T-cell lymphoma (AITL)

Mengmeng Dong, Yi Zhong, Fang Yu et al. Nov 03, 2025 pp. 7158-7158 10.1182/blood-2025-7158

Abstract Background : Angioimmunoblastic T-cell lymphoma (AITL), a distinct subtype of peripheral T-cell lymphoma (PTCL), presents with uni...

Modal CAR T cells: A synthetic cytokine circuit to overcome TGFβ-mediated immunosuppression in AML

FuGuo Liu, Xingyu Deng, Veronica Hui et al. Nov 03, 2025 pp. 4096-4096 10.1182/blood-2025-4096

Abstract Chimeric antigen receptor (CAR) T cells have shown clinical success in B and plasma cell derived hematologic malignancies, but dura...

High-throughput single-cell lipidomics reveals stage-specific phospholipid remodeling and ferroptosis-related signatures in the Evolution of plasma cell dyscrasia

Fujing Zhang, Chenxi Cao, Junling Zhuang et al. Nov 03, 2025 pp. 7458-7458 10.1182/blood-2025-7458

Abstract Introduction: Multiple myeloma (MM) evolves through a well-defined clinical continuum from monoclonal gammopath...

Temperature volatility as a novel environmental trigger for immune thrombocytopenia: A retrospective case-control study

Saion Chatterjee, Emma Kalle, Philip Choi Nov 03, 2025 pp. 6590-6590 10.1182/blood-2025-6590

Abstract Introduction: Immune thrombocytopenia (ITP) is an acquired autoimmune disorder marked by immune-mediated platelet destruction. Alth...

Neutrophil-TLR9 is a therapeutic target for acute chest syndrome in sickle cell disease

Ayyanar Sivanantham, Shane Howe, Nicholas Swendrowski et al. Nov 03, 2025 pp. 839-839 10.1182/blood-2025-839

Abstract Introduction: Acute chest syndrome (ACS), a severe form of acute lung injury, is a leading cause of morbidity and mortality in pati...

Post-treatment outcomes of TP53-mutant Mantle Cell Lymphoma patients treated with frontline zanubrutinib, obinutuzumab, and venetoclax (BOVen): Durable responses in patients who achieve complete remissions with undetectable MRD

Sean Healton, Jacob Soumerai, Jeffrey Barnes et al. Nov 03, 2025 pp. 3569-3569 10.1182/blood-2025-3569

Abstract Background: Mantle cell lymphoma (MCL) patients with TP53 mutations have poor outcomes with standard chemoimmunotherapy (Eskelund, B...

Initiation of ACE inhibitors or beta-blockers during frontline therapy for pediatric Acute Myeloid Leukemia and the impacts on cardiotoxicity incidence and survival outcomes: A target trial emulation

Quynh Long Khuong, Yimei Li, Jennifer Ko et al. Nov 03, 2025 pp. 876-876 10.1182/blood-2025-876

Abstract Background Anthracycline (ATC)-related cardiotoxicity is a well-recognized complication in pediatric acute myeloid leukemia (AML) a...

Comparative safety and efficacy of bendamustine versus fludarabine/cyclophosphamide prior to chimeric antigen receptor- T cell therapy: A systematic review and meta-analysis

Muhammad Kashif Amin, Tehseen Raza, Hira Habib et al. Nov 03, 2025 pp. 6320-6320 10.1182/blood-2025-6320

Abstract Background: CAR T-cell therapy is a promising treatment for certain leukemias and lymphomas, particularly refractory non-Hodgkin ly...

Molecular predictors of anemia response to momelotinib in patients with myelofibrosis: Real-world outcomes from the momgemfin study.

Adrian Segura Diaz, Lucia Perez Lamas, Ruth Stuckey et al. Nov 03, 2025 pp. 3808-3808 10.1182/blood-2025-3808

Abstract In patients with myelofibrosis (MF), driver mutation status, presence of additional mutations (especially of high-molecular risk, H...

Increased teclistamab dosing interval improves T-cell diversity and reduces infection risk, while T-cell exhaustion remains minimal irrespective of schedule

Nazia Afrin, Florian Eisele, Emilia Stanojkovska et al. Nov 03, 2025 pp. 802-802 10.1182/blood-2025-802

Abstract Introduction: Bispecific antibodies are among the most effective treatments for relapsed/refractory multiple myeloma (RRMM), induci...

Treosulfan-based vs. busulfan-based conditioning for hematopoietic stem cell transplantation: A systematic review and meta-analysis.

Ahmad Zulaid, Mahnoor Baloch, Faiqa Amin et al. Nov 03, 2025 pp. 5997-5997 10.1182/blood-2025-5997

Abstract Introduction Stem cell transplantation (SCT) continues to be a conventional treatment for many malignant and non-malignant hematolo...

National trends in sepsis-specific mortality among adults in the United States with multiple myeloma, a 24-year analysis

Love Kumar, Madho Mal, Amir Kamran Nov 03, 2025 pp. 8130-8130 10.1182/blood-2025-8130

Abstract Background: Multiple myeloma (MM) is associated with severe immunosuppression, increasing the risk of infection...

Updated clinical outcomes of a Phase I/II trial of bispecific CD19/CD20-targeted CAR-T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

Chuling Fang, Lixin Wang, Yuanyuan Zheng et al. Nov 03, 2025 pp. 1946-1946 10.1182/blood-2025-1946

Abstract Background: Non-Hodgkin lymphoma (NHL) is a common hematologic malignancy, and treatment options remain limited for patients with r...

Genome-wide CRISPR screening identifies CRL1 as a therapeutic target for restoring CD19 expression and improving immunotherapy efficacy in  B-cell malignancies

Narendra Varma Gottumukkala, Adriana Ladungová, Michael Doubek et al. Nov 03, 2025 pp. 4109-4109 10.1182/blood-2025-4109

Abstract Background: Antigen escape through CD19 downregulation is one of the key resistance mechanisms to CD19-targeted immunotherapies suc...

Pneumonia's impact on hospitalized Acute Myeloid Leukemia patient outcomes: A national inpatient sample study (Q4 2015 – 2022)

Najam Gohar, Haziq Ahmad, Arbab Kasi et al. Nov 03, 2025 pp. 6924-6924 10.1182/blood-2025-6924

Abstract Introduction Acute Myeloid Leukemia (AML), a crowding disease of the bone marrow, is associated with multiple in-hospital infection...

Immune reconstitution following memory T-cell add back and prophylactic blinatumomab post TCRαβ/CD19-depleted haploidentical transplantation in pediatric patients with high-risk acute leukemia

Shruthi Suryaprakash, Ying Li, Scott Perry et al. Nov 03, 2025 pp. 273-273 10.1182/blood-2025-273

Abstract TCRαβ depletion of haploidentical donor (haplo) grafts enables low rates of graft-versus-host disease (GVHD) but delays immune reco...

Burden and characteristics of infections in patients treated with bispecific antibodies and the impact of immunoglobulin replacement

Efstathios Kastritis, Eirini Solia, Ilias Katsadouros et al. Nov 03, 2025 pp. 2227-2227 10.1182/blood-2025-2227

Abstract Bispecific antibodies (BsAbs) targeting BCMA or GPRC5D have significantly improved outcomes in relapsed/refractory multiple myeloma...

Rising cardiovascular mortality among older adults with coexisting cancer and atrial fibrillation: A 25-year u.S. analysis (1999–2024).

Muhammad Shaheer Bin Faheem, Syed Tawassul Hassan, Anam Ashfaque et al. Nov 03, 2025 pp. 7898-7898 10.1182/blood-2025-7898

Abstract Background: Cardiovascular diseases (CVDs) remain the leading cause of mortality in the United States. Older adults with comorbid c...

Significant improvement of bone marrow fibrosis in patients with chronic myeloproliferative neoplasms (CMPN) treated with ruxolitinib.

Pablo Vargas-Viveros, Rafael Hurtado Monroy, Diana Mendoza-Elizarraraz et al. Nov 03, 2025 pp. 7333-7333 10.1182/blood-2025-7333

Abstract Ruxolitinib offers significant benefits for patients with myelofibrosis, particularly in enhancing survival rates and improving sym...

Disrupting a new NFkB-IL-6-JAK2-STAT cascade with novel NFkB inhibitors reduces primary myelofibrosis growth

Huiqin Bian, Naseema Gangat, Na Shen et al. Nov 03, 2025 pp. 1990-1990 10.1182/blood-2025-1990

Abstract Introduction: Primary myelofibrosis (PMF), a myeloproliferative neoplasm (MPN), features bone marrow fibrosis, splenomegaly, and ab...

Impact of voxelotor discontinuation on patients with sickle cell disease

Jin Han, Franklin Njoku, Marwah Farooqui et al. Nov 03, 2025 pp. 6150-6150 10.1182/blood-2025-6150

Abstract Introduction: Hemolysis in sickle cell disease (SCD) contributes to complications such as anemia, leg ulcers, and kidney dysfunctio...

Mortality patterns and geographic variation in acquired hemophilia A among Medicare beneficiaries in the United States

Tinatin Muradashvili, Mohamad Ali Tfaily, Stacey Fedewa et al. Nov 03, 2025 pp. 6240-6240 10.1182/blood-2025-6240

Abstract Acquired hemophilia A (AHA) is a rare but life-threatening autoimmune bleeding disorder caused by autoantibodies against factor VII...

Determinants of renal survival in patients treated for monoclonal gammopathy of renal significance

Samuel Rubinstein, Yusha Liu, Rajshekhar Chakraborty et al. Nov 03, 2025 pp. 3973-3973 10.1182/blood-2025-3973

Abstract Background: Monoclonal gammopathies of renal significance (MGRS) are a heterogeneous category of disorders characterized by renal dy...

Trends in acute TTP mortality amidst a shifting therapeutic landscape

Mathew Deucher, Madhumahita Maddukuri, Spero Cataland et al. Nov 03, 2025 pp. 4885-4885 10.1182/blood-2025-4885

Abstract Introduction: Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a potentially fatal disorder with a mortality rate of 9...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page